← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
HomeStocksGCTKRevenue History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

GCTK logoGlucoTrack, Inc. (GCTK) Revenue History

Annual and quarterly revenue from 2013 to 2024

TTM Revenue
$0
0
YoY Growth
-
Latest Quarter
$0
Q2 2025
QoQ Growth
-

Compound Annual Growth Rate (CAGR)

3-Year-
5-Year-
10-Year-
Highest Annual Revenue$612K (2016)
Highest Quarter$464K (Q4 2017)

Loading revenue history...

GCTK Revenue Growth

1-Year Growth
-
3-Year CAGR
-
5-Year CAGR
-
10-Year CAGR
-
TTM vs Prior Year-
Peak Annual Revenue$611,689 (2016)

Revenue Breakdown

GCTK's revenue distribution by segment and geography

By Geography

Europe99.9%
Asia and Pacific0.1%

Download Historical Data

12 records • Includes OHLCV + Technical Indicators (MA50, MA200, RSI)

Free sign in required to download data

GCTK Revenue Analysis (2013–2024)

As of May 8, 2026, GlucoTrack, Inc. (GCTK) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q2 2025) recorded $0 in revenue.

Looking at the longer-term picture, GCTK's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $611,689 in 2016.

When compared to Healthcare sector peers including DXCM (+16.2% YoY), PODD (+31.9% YoY), and TNDM (-6.8% YoY). Compare GCTK vs DXCM →

GCTK Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
GCTK logoGCTKCurrent$0---
DXCM logoDXCM$4.7B+16.2%+19.3%19.6%
PODD logoPODD$2.7B+31.9%+24.5%17.5%
TNDM logoTNDM$1.0B-6.8%+15.3%-7.7%
SENS logoSENS$35M+78.9%+48.1%-193.8%
Best in groupLowest in group

GCTK Historical Revenue Data (2013–2024)

Showing 10 of 12 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2024$0-$-36,000-$-14,547,000-
2023$0-$-13,000-$-7,104,000-
2022$0-$-23,000-$-4,432,000-
2021$0-$0-$-4,040,000-
2020$0-100.0%$-47,000-$-3,132,000-
2019$208K+378.3%$208K100.0%$3.5M1685.6%
2018$43K-92.6%$-52,075-119.7%$6.5M15035.4%
2017$589K-3.6%$449K76.2%$10.6M1794.2%
2016$612K+327.3%$552K90.3%$5.7M924.6%
2015$143K+139.5%$98K68.6%$4.7M3251.7%

See GCTK's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is GCTK Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare GCTK vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

GCTK — Frequently Asked Questions

Quick answers to the most common questions about buying GCTK stock.

Is GCTK's revenue growth accelerating or slowing?

GCTK TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.

What is GCTK's long-term revenue growth rate?

GlucoTrack, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.

How is GCTK's revenue distributed by segment?

GCTK reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

GCTK Revenue Over Time (2013–2024)